The MedsBase Situational Anxiety Treatment category is a misnomer worth understanding. Every product on this page is a chronic-use psychiatric medication — antidepressants (SSRIs, SNRIs, TCAs), atypical antipsychotics, or related agents prescribed and titrated over weeks for diagnosed mood, anxiety, and psychotic disorders. None of these drugs are first-line for acute, performance-related “situational” anxiety (flying, public speaking, exams, interviews) — for those situations, the clinically appropriate options are short-acting beta-blockers (propranolol), benzodiazepines, and sedating antihistamines (hydroxyzine), none of which are stocked in this category. If your need is occasional acute anxiety only, the medications below are not the right starting point. If your need is a diagnosed depressive, anxiety, bipolar, or psychotic disorder requiring long-term treatment, the index below organises what is here by drug class.
SSRIs — selective serotonin reuptake inhibitors
First-line antidepressants worldwide for major depressive disorder (MDD), generalised anxiety disorder (GAD), panic disorder, social anxiety disorder, OCD, PTSD, and PMDD. Onset 4–6 weeks for full mood response; anxiety symptoms often respond at 1–2 weeks. Common side effects are nausea, GI upset (usually transient), sexual dysfunction, and modest weight changes. Discontinuation must be tapered — never stopped abruptly.
Sertraline — the cleanest CYP profile of the SSRIs and preferred in pregnancy / breastfeeding: Sertafine, Sertagress, Sertima, Zosert (50/100 mg). Approved for MDD, OCD (adult and paediatric), panic, social anxiety, PTSD, PMDD.
Paroxetine — Xepar 20 mg. The SSRI with the broadest range of FDA-approved anxiety indications (MDD, GAD, social anxiety, panic, OCD, PTSD, PMDD). Trade-offs: worst discontinuation syndrome of the class (very short half-life), highest weight gain, highest sexual dysfunction, pregnancy category D.
SNRIs — serotonin-norepinephrine reuptake inhibitors
Second main first-line antidepressant class. Venlafaxine (extended-release) is approved for MDD, GAD, social anxiety, and panic disorder. Mechanism shifts with dose: SSRI-like below 150 mg/day, true SNRI (with norepinephrine reuptake inhibition) at 150–225 mg/day, with full effect in treatment-resistant depression at 225–375 mg/day in MDD. Distinctive concerns: dose-dependent blood-pressure rise (monitor BP at > 225 mg/day) and severe discontinuation syndrome (mandatory taper). More dangerous in overdose than SSRIs.
Affexor XR · Venish SR · Venpad XR · Ventab XL — all venlafaxine extended-release in 37.5 / 75 / 150 mg strengths.
Tricyclic antidepressants (TCAs) and TCA-related anxiolytics
Older antidepressant class largely replaced by SSRIs/SNRIs for first-line depression, but still useful for refractory depression, neuropathic pain, panic disorder, paediatric enuresis, and migraine prevention. Anticholinergic burden, sedation, orthostatic hypotension, and cardiac toxicity in overdose are the main concerns — baseline ECG before starting in patients over 50.
D-mine — imipramine 25 mg, the original tricyclic; for MDD, panic, paediatric enuresis, neuropathic pain.
Primox — nortriptyline 25 mg, the secondary-amine TCA with the lowest anticholinergic burden of the class; first-line tricyclic for migraine prevention and chronic neuropathic pain.
Opiprol — opipramol 50 mg, an atypical TCA-related anxiolytic that does niet inhibit serotonin reuptake (its mechanism is sigma-receptor agonism plus antihistamine); primary use is generalised anxiety disorder and somatoform disorders, mostly in German-speaking Europe.
Atypical antidepressants — mirtazapine, trazodone, vilazodone
Three drugs with mechanisms outside the SSRI / SNRI / TCA paradigm.
Nasdep — mirtazapine 30 mg, a tetracyclic NaSSA with strong H1 antihistamine activity. Paradoxical sedation pattern (more sedating at 15 mg than 45 mg). Major weight gain. Best matched to MDD with insomnia, low appetite, or weight loss, where the side effects work for the patient rather than against them.
Trazalon, Trazonil, Tridon — trazodone (50 / 100 mg). On-label for MDD but the dominant modern use is off-label low-dose (25–100 mg) for chronic insomnia. No dependence potential; main concerns are orthostatic hypotension (alpha-1 blockade), priapism in men (rare 1 in 1,000–10,000 — emergency if > 4 hours), and QT prolongation at higher doses.
Vilano — vilazodone 40 mg, an SSRI plus 5-HT1A partial agonist with lower sexual side-effects than other SSRIs. Must be taken with a ≥ 500-calorie meal — bioavailability halves on an empty stomach.
Atypical antipsychotics
Second-generation antipsychotics for schizophrenia, bipolar disorder, and adjunctive treatment of treatment-resistant depression. All carry an FDA black-box warning for increased mortality in elderly with dementia-related psychosis. Monitor weight, fasting glucose, and lipids at baseline, 3 months, then annually (metabolic syndrome is a class risk).
Psyquit · Q-Siz SR 400 — quetiapine in immediate-release and extended-release formulations. Heavy sedation; broad indications (schizophrenia, bipolar mania and depression, MDD adjunct).
Riscon — risperidone for schizophrenia, bipolar mania, and irritability in autism. Distinctive side-effect: highest hyperprolactinaemia of the atypicals (galactorrhoea, gynaecomastia, amenorrhoea, sexual dysfunction). Crosses into typical-antipsychotic-like EPS at doses > 6 mg/day.
Zipsydon — ziprasidone for schizophrenia and bipolar mania. Lowest metabolic burden of the common atypicals (less weight gain, less glucose / lipid impact) but highest QT prolongation (baseline ECG mandatory). Must be taken with a ≥ 500-calorie meal.
First-generation antipsychotic + anticholinergic combination
Trinicalm Plus — trifluoperazine 5 mg + trihexyphenidyl 2 mg. A high-potency typical antipsychotic paired with an anticholinergic anti-Parkinson agent to pre-empt the EPS (parkinsonism, dystonia, akathisia) that high-potency typical antipsychotics routinely cause. Used where typical antipsychotics remain first-line by cost or availability and in stable legacy regimens. Modern practice generally favours atypical antipsychotic monotherapy where available — lower EPS risk, lower tardive dyskinesia risk, and no routine anticholinergic cover required. Trihexyphenidyl has recognised abuse potential at supratherapeutic doses.
How to choose
For untreated MDD or anxiety disorders without prior treatment, sertraline is the most defensible first-line choice on the grounds of clean drug-interaction profile, broad indications, and pregnancy / breastfeeding safety. For MDD with prominent insomnia, low appetite, or weight loss, mirtazapine is a sensible alternative because the side effects work in the patient’s favour. For chronic insomnia not responding to behavioural interventions, low-dose trazodone remains the most-prescribed off-label hypnotic globally. For schizophrenia or bipolar I disorder, an atypical antipsychotic (quetiapine, risperidone, ziprasidone) is first-line over typical antipsychotics in modern practice. None of these drugs replaces individualised psychiatric assessment — the right choice depends on diagnosis, comorbidity, prior treatment history, drug interactions, and pregnancy status.
Genuine WHO-GMP certified manufacturer stock · discreet packaging · worldwide shipping · 1,400+ customers across 50+ countries. Elke bestelling wordt gedekt door onze Reshipment Assurance Policy.